HCW Biologics Inc.
HCWB
$4.99
-$0.27-5.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 356.14% | -97.88% | -87.93% | -78.77% | -63.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 356.14% | -97.88% | -87.93% | -78.77% | -63.19% |
| Cost of Revenue | -95.42% | -97.30% | -85.71% | -75.33% | -60.23% |
| Gross Profit | 1,792.31% | -98.87% | -92.55% | -86.37% | -70.26% |
| SG&A Expenses | -49.77% | -54.62% | -69.86% | -68.59% | -10.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.20% | -48.78% | -63.61% | -63.27% | -17.93% |
| Operating Income | 65.57% | 44.31% | 61.24% | 61.64% | 11.55% |
| Income Before Tax | 92.08% | 73.49% | 67.72% | 70.29% | 9.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 90.75% | 73.49% | 67.72% | 70.29% | 9.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.75% | 73.49% | 67.72% | 70.29% | 9.63% |
| EBIT | 65.57% | 44.31% | 61.24% | 61.64% | 11.55% |
| EBITDA | 66.84% | 45.72% | 64.86% | 64.86% | 13.06% |
| EPS Basic | 62.82% | 62.56% | 65.26% | 61.32% | 15.71% |
| Normalized Basic EPS | 82.59% | 70.26% | 72.68% | 67.30% | 14.34% |
| EPS Diluted | 62.82% | 62.56% | 65.26% | 61.32% | 15.71% |
| Normalized Diluted EPS | 82.59% | 70.26% | 72.68% | 67.30% | 14.34% |
| Average Basic Shares Outstanding | 216.07% | 120.15% | 66.98% | 33.36% | 12.11% |
| Average Diluted Shares Outstanding | 216.07% | 120.15% | 66.98% | 33.36% | 12.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |